3 results match your criteria: "and Rheumatology) Nippon Medical School[Affiliation]"
SATISFY-JP, a phase II multicenter open-label study on Satralizumab, an anti-IL-6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune-responsive-phenotype: Study protocol.
Pulm Circ
April 2023
Department of Allergy and Rheumatology Nippon Medical School Hospital Tokyo Japan.
Article Synopsis
- - Pulmonary arterial hypertension (PAH) is a serious condition that typically requires treatments like pulmonary vasodilators, but new drug developments are exploring different mechanisms, particularly targeting specific patient needs.
- - A connection has been found between interleukin-6 (IL-6) levels and PAH, leading researchers to investigate this cytokine as a potential target for treatment in patients showing elevated IL-6.
- - A clinical study is currently being conducted to see if an antibody called satralizumab can effectively treat PAH in patients identified through biomarker profiles, focusing on those with increased IL-6 levels.
Thrombosis in Japanese patients with Fabry disease.
J Neurol Sci
August 2009
Department of Internal Medicine (Divisions of Neurology, Nephrology, and Rheumatology) Nippon Medical School, Tokyo, Japan.
Fabry disease is an X-linked lysosomal storage disease resulting from deficient activity of the enzyme alpha-galactosidase (alpha-Gal) A. It has been postulated that the accumulation of globotriaosylceramide in the endothelial cells of blood vessels may lead to thrombosis of the brain and other tissues. Recently, enzyme replacement therapy (ERT) for Fabry disease is available.
View Article and Find Full Text PDFEffects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis.
Clin Chim Acta
February 2007
Department of Internal Medicine (Divisions of Neurology, Nephrology, and Rheumatology) Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Background: Arteriosclerosis obliterans (ASO) is a serious complication in patients with end-stage renal disease (ESRD) caused by diabetic nephropathy. Adsorption of low-density lipoprotein (LDL) has been performed to treat ASO. While efficacy of this treatment has been reported in limb ischemia, the mechanism underlying the benefit remains unclear.
View Article and Find Full Text PDF